Trending...
- EIG Global Trust Unveils Groundbreaking Gold Backed Digital Currency Stablecoin Ecosystem Poised to Accelerate the Global Digital Asset Transformation - 113
- SQUARESIGNS Featured in Inc.5000 List Again - 109
- CCHR Warns Global Survey Confirms Electroshock Risks Hidden From Public
~ Neuromod USA Inc. has recently been awarded a Federal Supply Schedule 65 II Medical Equipment and Supply Contract from the US Government, making their Lenire tinnitus device available as a treatment option for the 2.9 million US veterans living with tinnitus through the Department of Veterans Affairs (VA). This marks a significant milestone for Neuromod as Lenire is the first and only bimodal neuromodulation device to receive such recognition.
The General Services Administration FSS Contract will also make Lenire an option for patients receiving care from other government agencies such as the Department of Defense (DoD), Bureau of Prisons, Indian Health Services, and Public Health Services. This means that more patients suffering from tinnitus will now have access to this innovative treatment option.
Tinnitus, commonly known as "ringing in the ears," is a complex neurological condition that affects an estimated ten percent of all adults. It causes a perception of sound when there is no external source, and if left untreated, it can significantly impact a person's quality of life. In fact, tinnitus has been the number one service-connected disability compensated for by the VA since 1955, with over 2.9 million veterans receiving more than $5 billion in compensation in 2023 alone.
More on illi News
Eric Timm, CEO of Neuromod USA and President of Global Commercial Operations at Neuromod Devices, stated that "tinnitus is the number one service-connected disability" and that "the number of veterans with tinnitus is growing at a double-digit rate annually." He also emphasized how Neuromod's FSS Contract ensures that current and future veterans have access to clinically proven tinnitus treatment technology.
Lenire's bimodal neuromodulation works by pairing specially designed tones heard through wireless headphones with mild electrical pulses that stimulate the tongue through a component called the Tonguetip®. This unique approach has shown promising results in clinical trials, leading to Lenire becoming the first tinnitus treatment device to be awarded FDA Approval through the De Novo framework in March 2023.
The FDA Approval was granted based on the success of Lenire's controlled large-scale clinical trial, TENT-A3, which confirmed its superiority over sound-only stimulation. In fact, 70.5% of patients with moderate or worse tinnitus who did not report clinically significant improvement from six weeks of sound-only stimulation reported significant improvement after six weeks of treatment with Lenire. Additionally, the majority of patients who benefitted from sound-only stimulation also experienced further improvement with an additional six weeks of treatment with Lenire.
More on illi News
Furthermore, nearly 89 percent of clinical trial participants would recommend Lenire as a treatment option for tinnitus. This is a testament to the effectiveness and potential impact that this device can have on those suffering from this debilitating condition.
With the FSS Contract now in place, Neuromod is committed to providing access to this groundbreaking technology for veterans and other patients in need. As Timm stated, "Everyone at Neuromod is privileged to be serving our veterans by doing our part for tinnitus care."
The General Services Administration FSS Contract will also make Lenire an option for patients receiving care from other government agencies such as the Department of Defense (DoD), Bureau of Prisons, Indian Health Services, and Public Health Services. This means that more patients suffering from tinnitus will now have access to this innovative treatment option.
Tinnitus, commonly known as "ringing in the ears," is a complex neurological condition that affects an estimated ten percent of all adults. It causes a perception of sound when there is no external source, and if left untreated, it can significantly impact a person's quality of life. In fact, tinnitus has been the number one service-connected disability compensated for by the VA since 1955, with over 2.9 million veterans receiving more than $5 billion in compensation in 2023 alone.
More on illi News
- Chicago: Mayor Brandon Johnson Releases FY2026 Budget Forecast
- Mayor Johnson, Chicago Department Of Aviation To Roll Out 'Papa Blu' Community Outreach Vehicle
- Integris Composites Joins Pacific Future Forum in Tokyo
- TEAMSTERS SECURE ANOTHER WIN AT ASCEND CANNABIS IN ILLINOIS
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
Eric Timm, CEO of Neuromod USA and President of Global Commercial Operations at Neuromod Devices, stated that "tinnitus is the number one service-connected disability" and that "the number of veterans with tinnitus is growing at a double-digit rate annually." He also emphasized how Neuromod's FSS Contract ensures that current and future veterans have access to clinically proven tinnitus treatment technology.
Lenire's bimodal neuromodulation works by pairing specially designed tones heard through wireless headphones with mild electrical pulses that stimulate the tongue through a component called the Tonguetip®. This unique approach has shown promising results in clinical trials, leading to Lenire becoming the first tinnitus treatment device to be awarded FDA Approval through the De Novo framework in March 2023.
The FDA Approval was granted based on the success of Lenire's controlled large-scale clinical trial, TENT-A3, which confirmed its superiority over sound-only stimulation. In fact, 70.5% of patients with moderate or worse tinnitus who did not report clinically significant improvement from six weeks of sound-only stimulation reported significant improvement after six weeks of treatment with Lenire. Additionally, the majority of patients who benefitted from sound-only stimulation also experienced further improvement with an additional six weeks of treatment with Lenire.
More on illi News
- The Emotional Stages of Foreclosure — And How 4Closure Rescue LLC Helps Families Cope
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
- AureaVault Launches U.S.-Licensed Cryptocurrency Exchange with Enhanced Security Features
- IOTAP Named to 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Furthermore, nearly 89 percent of clinical trial participants would recommend Lenire as a treatment option for tinnitus. This is a testament to the effectiveness and potential impact that this device can have on those suffering from this debilitating condition.
With the FSS Contract now in place, Neuromod is committed to providing access to this groundbreaking technology for veterans and other patients in need. As Timm stated, "Everyone at Neuromod is privileged to be serving our veterans by doing our part for tinnitus care."
Filed Under: Business
0 Comments
Latest on illi News
- ShortTrack Expands Partnership with Qualia
- MARIAH THE SCIENTIST'S HIT SINGLE "BURNING BLUE" EARNS RIAA GOLD CERTIFICATION
- Naperville Police Arrest Bolingbrook Man for Unlawful Recording in Public Restrooms
- Chicago: ICYMI: Mayor Brandon Johnson Awards Second Cohort Of Victim Services Advocates At Graduation Ceremony
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- Inkdnylon Partners with Original Favorites to Deliver Luxury Blank Apparel with Custom Decoration in Chicago & Nationwide
- The Top 5 Mistakes Homeowners Make During Foreclosure -How 4Closure Rescue LLC Helps Avoid Them
- Digi 995: Magic Match 3 Surpasses Early Milestones as Player Community Expands
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- Serve to Soar: Dominique Brightmon on Advancing Others & Elevating Yourself
- AI Geology Estimator Predicts Well Depths Nationwide - DrillerDB Launches Tool for U.S. Homeowners a
- From Vernon Hills to Mensa Before Kindergarten
- Fine Arts Festival Downtown Downers Grove
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality
- Allen Field to Showcase Sustainable Paper Handle Applicator at PACK EXPO Las Vegas 2025
- Chicago Paper Artist Janie Flores Joins Illinois Humanities Odyssey Project 2025 Cohort